Stocktoria
Enlivex Ltd. ENLV
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-07-30
Enlivex Ltd. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $9.2M | $10.6M | $19.0M | $18.7M | $12.9M |
| Operating income | -$15.0M | -$15.9M | -$29.4M | -$25.8M | -$19.3M |
| Income tax | $382.6M | — | — | — | — |
| Net income | $1.2B | -$15.0M | -$29.1M | -$31.1M | -$14.5M |
| EPS (diluted) | $25.48 | $-0.73 | $-1.56 | $-1.69 | $-0.81 |
| Operating cash flow | -$10.4M | -$13.0M | -$23.5M | -$24.0M | -$17.5M |
| Free cash flow | -$10.5M | -$13.1M | -$23.8M | -$32.1M | -$19.2M |
| Cash & equivalents | $1.9M | $3.3M | $813,000 | $49.9M | $11.2M |
| Total assets | $2.3B | $27.7M | $36.8M | $67.6M | $95.1M |
| Total liabilities | $392.1M | $4.1M | $6.7M | $10.8M | $10.1M |
| Shareholders' equity | $1.9B | $23.6M | $30.1M | $56.8M | $85.0M |
Source: SEC EDGAR filings · CIK 0001596812 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.